Research library
Peptide Support/peptide

VIP

Canonical identity: Vasoactive intestinal peptide

Also indexed as: Vasoactive Intestinal Peptide

An endogenous neuropeptide with broad receptor biology and indication-specific research.

Evidence level

Human research, limited or context-specific

Verified against the linked source set on 2026-08-20.

What it is

VIP is a naturally occurring peptide neurotransmitter and hormone studied across gastrointestinal, pulmonary, immune, and vascular biology.

Mechanism and research questions

  • VIP signals through VPAC1 and VPAC2 receptors and can influence cAMP-linked pathways.
  • Those receptor signals can alter secretion, smooth-muscle tone, vascular responses, and immune-cell behavior depending on the tissue and experimental conditions.

Human evidence

Human studies exist across specific diseases and physiologic contexts; evidence must be interpreted by indication and formulation.

Preclinical / mechanistic evidence

Mechanistic and animal research spans immune, pulmonary, neural, and gastrointestinal models.

Evidence summary

VIP has a large scientific literature, but a broad literature count is not evidence for a specific catalog use.

Limits and interpretation

  • Very broad biology makes indication-specific sourcing essential.
  • Do not infer therapeutic effect from receptor activity alone.
  • No dosing or medical-use instructions are provided.

Regulatory and identity note

Research-use peptide; not presented as a general approved treatment.

Research summaries reflect primary literature, patent landscapes, and regulatory status reports at the time of review. They do not constitute therapeutic advice, endorsement, or claims regarding unauthorized preparations.